HLS Therapeutics Revenue and Competitors

Toronto, ON CAN

Location

$192.2M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • HLS Therapeutics's estimated annual revenue is currently $17.9M per year.(i)
  • HLS Therapeutics received $125.0M in venture funding in September 2018.
  • HLS Therapeutics's estimated revenue per employee is $192,355
  • HLS Therapeutics's total funding is $192.2M.

Employee Data

  • HLS Therapeutics has 93 Employees.(i)
  • HLS Therapeutics grew their employee count by 3% last year.

HLS Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
SVP, Legal, HR and ComplianceReveal Email/Phone
4
VP Scientific AffairsReveal Email/Phone
5
Associate Director MarketingReveal Email/Phone
6
Director FinanceReveal Email/Phone
7
Director, Medical Affairs - CardiovascularReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Senior Director, Human ResourcesReveal Email/Phone
10
Brand Manager NeuroscienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$18.5M92-1%N/AN/A
#2
$14.3M716%N/AN/A
#3
$36M1798%N/AN/A
#4
$7.8M398%N/AN/A
#5
$17.9M933%$192.2MN/A
#6
$64.9M3234%N/AN/A
#7
$0.5M5-55%N/AN/A
#8
$6.8M34-41%N/AN/A
#9
$19.5M9723%N/AN/A
#10
$2.5M2519%N/AN/A
Add Company

What Is HLS Therapeutics?

The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. Who We Are HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug's originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada's regulations. Our Goal/Our Mission HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.

keywords:N/A

$192.2M

Total Funding

93

Number of Employees

$17.9M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HLS Therapeutics News

2022-04-17 - HLS Therapeutics is a Buy, says Stifel

Stifel GMP analyst Justin Keywood remains in a positive headspace about HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News,...

2022-04-13 - HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05

HLS Therapeutics is not generating a profit, but its free cash flows easily cover the dividend, leaving plenty for reinvestment in the business.

2022-03-22 - HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05

HLS Therapeutics Inc.'s (TSE:HLS) investors are due to receive a payment of CA$0.05 per share on 15th of June.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M10110%N/A
#2
$32.5M1128%N/A
#3
$28.4M11338%N/A
#4
$23.7M1139%N/A
#5
$33.8M125-5%N/A

HLS Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-09-13$125.0MUndisclosedSilicon Valley BankArticle